CDD signs partnership agreement with Myelin Repair Foundation

Myelin Repair Foundation’s (MRF) Accelerated Research Collaboration (ARC) model creates a unique partnership between academic researchers, scientific and drug discovery advisors and a centralized management team to define and execute on an integrated research plan that will reduce the time to market for a wide range of patient treatments.

Focused exclusively at this time on identifying myelin repair drug targets that will lead to treatments for multiple sclerosis by 2009, MRF provides the business infrastructure for a team of some 30 scientists, working together virtually, from different university laboratories in the US.

The Collaborative Drug Discovery’s (CDD) software is said to excel at capturing and organizing fragmented data that would otherwise remain dispersed across multiple laboratories. The central database maintains research continuity as participants change and ensures continued access to the results of sponsored research.

In addition to making its existing capabilities available to all MRF researchers, CDD will extend the software’s range to include target validation and customize the interface for MRF’s researchers. MRF and CDD will also work together to help other disease research organizations realize the full potential of collaborative research.

Rusty Bromley, COO of MRF, said: “Part of our mission is to enable others to reap the benefits of the ARC model for preclinical drug discovery R&D. A successful partnership with CDD will offer proof of concept to others seeking collaboration tools for similar research efforts.”